Precemtabart Tocentecan

3 trials 1 recruiting

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

1 Recruiting

2 Completed trials

1 Sponsors

5 Countries

Phase I/II

Phase I/II: 3

Indications tested

Metastatic gastric cancer 1 Pancreatic carcinoma metastatic 1 Non-small cell lung cancer metastatic 1

Sponsors using this IMP

Merck Healthcare KGaA 3

All trials

3 total

Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Pancreatic Cancer (Substudy PDAC) Recruiting

2024-517819-74-00 Phase I/II 5 countries Merck Healthcare KGaA
Phase 1b/2 Study of Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Participants With Advanced Gastric Cancer (Substudy GC) Ended

2024-517817-34-00 Phase I/II 5 countries Merck Healthcare KGaA
Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced NSCLC (Substudy NSCLC) Ended

2024-517818-15-00 Phase I/II 5 countries Merck Healthcare KGaA

Showing 1–3 of 3 trials

← All drugs A–Z